Last updated: May 2, 2026
Who supplies MIBELAS 24 FE (pharmaceutical drug)?
MIBELAS 24 FE is a brand of an oral contraceptive. It is supplied in the U.S. by TherapeuticsMD, Inc. (brand owner/labeler) and manufactured under contract by established generic and branded-Oc supplier networks. However, the specific drug-product manufacturer name (the actual listed manufacturer on the FDA label) and the excipient and packaging suppliers are not identifiable from the information provided here.
What supplier identity can be stated from the brand labeling record?
Labeler / marketing authorization holder
- TherapeuticsMD, Inc. is the listed labeler for MIBELAS 24 FE in U.S. product labeling records.
Product manufacturer
- The specific finished-dose manufacturer (the “Manufactured for…” / “Manufactured by…” entity) is not provided in the prompt, so it cannot be stated accurately.
What supplier types typically exist for MIBELAS 24 FE?
For this class of drug (combined oral contraceptive tablets), supplier stack usually breaks into:
- Labeler / marketer (brand owner)
- Finished-dose manufacturer (tablet manufacture, film coating, blistering or bottle filling)
- API suppliers (active ingredients: the estrogen and progestin components)
- Excipients and packaging suppliers (tablet cores, coating systems, blister components, bottles, desiccants if used)
Only the labeler can be affirmed from the provided context.
Supplier mapping you can use for diligence
Contract manufacturing due-diligence checkpoints
- Identify the finished-dose manufacturer named on the U.S. carton and package insert.
- Verify whether the same site also manufactures the identical dosage form for the labeler’s other oral contraceptive SKUs.
- Confirm GMP compliance for the manufacturing site via FDA inspection outcomes and consent decree history where applicable.
API due-diligence checkpoints
- Map the estrogen and progestin APIs to:
- Commercial supplier used for DMF-backed supply
- Particle-size and polymorph controls where relevant
- Synthesis intermediates and whether they are sourced from the same upstream vendor set
Packaging due-diligence checkpoints
- Determine the primary packaging configuration:
- Blister vs bottle
- Child-resistant packaging requirements for the marketed SKU
- Film and aluminum foil supplier qualification status (where disclosed to buyers)
Key Takeaways
- TherapeuticsMD, Inc. is the labeler/marketing supplier identity for MIBELAS 24 FE in U.S. labeling.
- The finished-dose manufacturer and API/excipient/packaging suppliers cannot be identified from the supplied information, so they cannot be stated as facts here.
- For R&D or investment diligence, the fastest path is to extract the “Manufactured for/Manufactured by” line from the official package insert/carton and then map that site to API and packaging qualification records.
FAQs
1) Who is the labeler (brand supplier) for MIBELAS 24 FE?
TherapeuticsMD, Inc.
2) Who manufactures the finished tablets for MIBELAS 24 FE?
The finished-dose manufacturer is not provided in the prompt, so it cannot be stated.
3) Are there multiple manufacturers or a single contract site for this SKU?
The supplier structure is not provided here; multiple-site supply is possible in practice but cannot be asserted without label/package data.
4) Can API suppliers be determined from the drug name alone?
No. API suppliers require label-level or regulatory dossier references that are not included in the prompt.
5) Where do you verify the supplier chain for a specific MIBELAS 24 FE lot?
Use the official U.S. labeling (package insert/carton) for the named manufacturer, then trace to GMP site records and quality documentation for the lot.
References (APA)
[1] FDA. (n.d.). Drug databases: Label information (DailyMed). U.S. Food and Drug Administration. https://dailymed.nlm.nih.gov/
